Megalis 10 mg contains tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor commonly used to treat erectile dysfunction (ED). However, it is also sometimes preferred for treating symptoms of benign prostatic hyperplasia (BPH)—a non-cancerous enlargement of the prostate gland that affects urination in men.
Tadalafil helps relax smooth muscles in the bladder and prostate, improving urine flow and reducing symptoms such as frequent urination, urgency, weak stream, and nighttime urination (nocturia). Megalis 10 mg offers a convenient once-daily dosing, providing continuous symptom relief without the need for multiple medications.
One reason MEGALIS 10 MG is preferred is its dual benefit: it can treat both BPH and ED, conditions that often occur together in aging men. This simplifies treatment and improves compliance, as a single medication addresses two issues.
Additionally, tadalafil has a long half-life (up to 36 hours), which allows for sustained therapeutic effects. Compared to alpha-blockers or 5-alpha-reductase inhibitors used in BPH, tadalafil may cause fewer sexual side effects, such as decreased libido or erectile difficulties.
In summary, Megalis 10 mg is preferred in some cases for BPH because of its effectiveness, once-daily dosing, and added benefit for men who also experience ED.
Add your comment